These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

785 related articles for article (PubMed ID: 22062804)

  • 1. Second autologous stem cell transplantation as salvage therapy for multiple myeloma: impact on progression-free and overall survival.
    Jimenez-Zepeda VH; Mikhael J; Winter A; Franke N; Masih-Khan E; Trudel S; Chen C; Kukreti V; Reece DE
    Biol Blood Marrow Transplant; 2012 May; 18(5):773-9. PubMed ID: 22062804
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Autologous stem cell transplantation: an effective salvage therapy in multiple myeloma.
    Lemieux E; Hulin C; Caillot D; Tardy S; Dorvaux V; Michel J; Gastinne T; Rossi C; Legouge C; Touzeau C; Planche L; Loirat M; Lafon I; Moreau P
    Biol Blood Marrow Transplant; 2013 Mar; 19(3):445-9. PubMed ID: 23186983
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Melphalan 100 mg/m2 with stem cell support as first relapse treatment is safe and effective for myeloma patients with long remission after autologous stem cell transplantation.
    Blimark C; Veskovski L; Westin J; Rödjer S; Brune M; Hjorth M; Holmberg E; Andersson PO; Mellqvist UH
    Eur J Haematol; 2011 Aug; 87(2):117-22. PubMed ID: 21535157
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prolonged overall survival with second on-demand autologous transplant in multiple myeloma.
    Elice F; Raimondi R; Tosetto A; D'Emilio A; Di Bona E; Piccin A; Rodeghiero F
    Am J Hematol; 2006 Jun; 81(6):426-31. PubMed ID: 16680735
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Relapsed multiple myeloma: who benefits from salvage autografts?
    Chow AW; Lee CH; Hiwase DK; To LB; Horvath N
    Intern Med J; 2013 Feb; 43(2):156-61. PubMed ID: 22757772
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Autologous retransplantation for patients with recurrent multiple myeloma: a single-center experience with 200 patients.
    Sellner L; Heiss C; Benner A; Raab MS; Hillengass J; Hose D; Lehners N; Egerer G; Ho AD; Goldschmidt H; Neben K
    Cancer; 2013 Jul; 119(13):2438-46. PubMed ID: 23576287
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Complete remission status before autologous stem cell transplantation is an important prognostic factor in patients with multiple myeloma undergoing upfront single autologous transplantation.
    Kim JS; Kim K; Cheong JW; Min YH; Suh C; Kim H; Jo DY; Ryoo HM; Yoon SS; Lee JH;
    Biol Blood Marrow Transplant; 2009 Apr; 15(4):463-70. PubMed ID: 19285634
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Autologous stem cell transplantation in multiple myeloma: improved survival in nonsecretory multiple myeloma but lack of influence of age, status at transplant, previous treatment and conditioning regimen. A single-centre experience in 127 patients.
    Terpos E; Apperley JF; Samson D; Giles C; Crawley C; Kanfer E; Olavarria E; Goldman JM; Rahemtulla A
    Bone Marrow Transplant; 2003 Feb; 31(3):163-70. PubMed ID: 12621476
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Consolidation therapy with low-dose thalidomide and prednisolone prolongs the survival of multiple myeloma patients undergoing a single autologous stem-cell transplantation procedure.
    Spencer A; Prince HM; Roberts AW; Prosser IW; Bradstock KF; Coyle L; Gill DS; Horvath N; Reynolds J; Kennedy N
    J Clin Oncol; 2009 Apr; 27(11):1788-93. PubMed ID: 19273705
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [High-dose chemotherapy and autologous stem cell transplantation in multiple myeloma patients--single center experience].
    Piatkowska-Jakubas B; Wolska-Smoleń T; Mensah-Glanowska P; Hawrylecka D; Szostek M; Walter Z; Skotnicki AB
    Przegl Lek; 2011; 68(2):78-81. PubMed ID: 21751514
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Short-term thalidomide incorporated into double autologous stem-cell transplantation improves outcomes in comparison with double autotransplantation for multiple myeloma.
    Cavo M; Di Raimondo F; Zamagni E; Patriarca F; Tacchetti P; Casulli AF; Volpe S; Perrone G; Ledda A; Ceccolini M; Califano C; Bigazzi C; Offidani M; Stefani P; Ballerini F; Fiacchini M; de Vivo A; Brioli A; Tosi P; Baccarani M
    J Clin Oncol; 2009 Oct; 27(30):5001-7. PubMed ID: 19720903
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy of up-front treatment with a double stem cell transplantation in multiple myeloma.
    Eom KS; Min CK; Lee S; Kim YJ; Kim SY; Kim HJ; Lee JW; Min WS; Kim CC
    Jpn J Clin Oncol; 2006 Jul; 36(7):432-8. PubMed ID: 16782727
    [TBL] [Abstract][Full Text] [Related]  

  • 13. "Short course" bortezomib plus melphalan and prednisone as induction prior to transplant or as frontline therapy for nontransplant candidates in patients with previously untreated multiple myeloma.
    Gasparetto C; Gockerman JP; Diehl LF; de Castro CM; Moore JO; Long GD; Horwitz ME; Keogh G; Chute JP; Sullivan KM; Neuwirth R; Davis PH; Sutton LM; Anderson RD; Chao NJ; Rizzieri D
    Biol Blood Marrow Transplant; 2010 Jan; 16(1):70-7. PubMed ID: 19733251
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A 15-year analysis of early and late autologous hematopoietic stem cell transplant in relapsed, aggressive, transformed, and nontransformed follicular lymphoma.
    Sabloff M; Atkins HL; Bence-Bruckler I; Bredeson C; Fergusson D; Genest P; Hopkins H; Hutton B; Mcdiarmid S; Huebsch LB
    Biol Blood Marrow Transplant; 2007 Aug; 13(8):956-64. PubMed ID: 17640600
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Predictive factors for survival in myeloma patients who undergo autologous stem cell transplantation: a single-centre experience in 211 patients.
    O'Shea D; Giles C; Terpos E; Perz J; Politou M; Sana V; Naresh K; Lampert I; Samson D; Narat S; Kanfer E; Olavarria E; Apperley JF; Rahemtulla A
    Bone Marrow Transplant; 2006 Apr; 37(8):731-7. PubMed ID: 16501593
    [TBL] [Abstract][Full Text] [Related]  

  • 16. High-dose melphalan is an effective salvage therapy in acute myeloid leukaemia patients with refractory relapse and relapse after autologous stem cell transplantation.
    Bug G; Atta J; Klein SA; Hertenstein B; Bergmann L; Boehrer S; Mousset S; Hoelzer D; Martin H
    Ann Hematol; 2005 Oct; 84(11):748-54. PubMed ID: 16001243
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The effect of salvage autologous stem-cell transplantation on overall survival in patients with relapsed multiple myeloma (final results from BSBMT/UKMF Myeloma X Relapse [Intensive]): a randomised, open-label, phase 3 trial.
    Cook G; Ashcroft AJ; Cairns DA; Williams CD; Brown JM; Cavenagh JD; Snowden JA; Parrish C; Yong K; Cavet J; Hunter H; Bird JM; Pratt G; Chown S; Heartin E; O'Connor S; Drayson MT; Hockaday A; Morris TC;
    Lancet Haematol; 2016 Jul; 3(7):e340-51. PubMed ID: 27374467
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Autologous stem cell transplantation in first remission is associated with better progression-free survival in multiple myeloma.
    Aggarwal M; Agrawal N; Yadav N; Verma P; Ahmed R; Mehta P; Kapoor J; Bhurani D
    Ann Hematol; 2018 Oct; 97(10):1869-1877. PubMed ID: 29781040
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Role of salvage radiation therapy for patients with relapsed or refractory hodgkin lymphoma who failed autologous stem cell transplant.
    Goda JS; Massey C; Kuruvilla J; Gospodarowicz MK; Wells W; Hodgson DC; Sun A; Keating A; Crump M; Tsang RW
    Int J Radiat Oncol Biol Phys; 2012 Nov; 84(3):e329-35. PubMed ID: 22672755
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Higher infused lymphocyte dose predicts higher lymphocyte recovery, which in turn, predicts superior overall survival following autologous hematopoietic stem cell transplantation for multiple myeloma.
    Hiwase DK; Hiwase S; Bailey M; Bollard G; Schwarer AP
    Biol Blood Marrow Transplant; 2008 Jan; 14(1):116-24. PubMed ID: 18158968
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 40.